Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Konica Minolta’s US Subsidiary to Launch PCR Testing Platform
April 20, 2020
- Takeda, Tohoku University Ink Joint Research Pact on Whole Genome Sequencing
April 20, 2020
- Big 3 Generic Makers to Discontinue Procaterol Tablets as API Procurement Stalls
April 17, 2020
- Sunovion’s Novel Schizophrenia Med Smashes Primary Goals in US PII Study
April 17, 2020
- Novartis Japan Staffer Infected with Coronavirus
April 16, 2020
- Vibegron Prescription Soars after 14-Day Limit Lifted, Triggering Shipment Curbs
April 16, 2020
- Gilead Japan to Seek Early Remdesivir Filing If Initial Data Prove Positive: Development Chief
April 16, 2020
- J&J’s TachoSil Deal Dropped on Antitrust Issues; Takeda Mum on Future Plan
April 16, 2020
- Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
- PeptiDream Ties Up with PeptiGrowth on Development of Peptide Alternatives
April 16, 2020
- Kyowa Kirin Snags Global Rights to MEI’s Blood Cancer Drug in Expanded Deal
April 15, 2020
- Novartis’ Japan Sales Jump to 330.5 Billion Yen on Alcon Integration
April 15, 2020
- Lilly’s Japan Sales Grow 4.5% to 275 Billion Yen in 2019
April 15, 2020
- Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
- Shionogi Aiming at Clinical Trials of COVID-19 Treatment Candidates in FY2020
April 15, 2020
- Peptide Institute Latest to Chip In with AnGes to Develop Novel Coronavirus Vaccine
April 15, 2020
- Gilead Launches PIII Remdesivir Trials for COVID-19 in Japan
April 15, 2020
- Sosei Kicks Off COVID-19 Drug Discovery Program
April 15, 2020
- Sanofi Files Sutimlimab for Cold Agglutinin Disease in Japan
April 14, 2020
- Opdivo Adds New Indication for Esophageal Cancer in South Korea
April 14, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…